Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02020941
What this trial is testing

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Who this might be right for
Refractory Multiple Myeloma
Attaya Suvannasankha 10
Early research (Phase 1)Looking for participantsNCT07409246
What this trial is testing

Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 127
Testing effectiveness (Phase 2)Study completedNCT01155583
What this trial is testing

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Case Comprehensive Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT00049374
What this trial is testing

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Study completedNCT02654990
What this trial is testing

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
pharmaand GmbH 248
Testing effectiveness (Phase 2)Looking for participantsNCT07181941
What this trial is testing

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Testing effectiveness (Phase 2)Ended earlyNCT00857324
What this trial is testing

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Tiziana Marangon 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04756401
What this trial is testing

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Academic and Community Cancer Research United 8
Early research (Phase 1)UnknownNCT05325801
What this trial is testing

CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Zhejiang University 9
Early research (Phase 1)UnknownNCT03674463
What this trial is testing

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University 10
Testing effectiveness (Phase 2)Ended earlyNCT00368121
What this trial is testing

EMMA-1 (Erbitux for Multiple Myeloma)

Who this might be right for
Multiple Myeloma
Prof. Dr. Andreas Engert 13
Early research (Phase 1)Looking for participantsNCT05976555
What this trial is testing

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Who this might be right for
Multiple Myeloma
Medical College of Wisconsin 30
Early research (Phase 1)Study completedNCT01497093
What this trial is testing

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 34
Testing effectiveness (Phase 2)Study completedNCT00022607
What this trial is testing

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
California Cancer Consortium
Testing effectiveness (Phase 2)Study completedNCT00378209
What this trial is testing

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 65
Large-scale testing (Phase 3)Looking for participantsNCT07623798
What this trial is testing

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd. 255
Testing effectiveness (Phase 2)Study completedNCT01063907
What this trial is testing

KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Kyowa Kirin Co., Ltd. 95
Not applicableLooking for participantsNCT07559799
What this trial is testing

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

Who this might be right for
Multiple Myeloma
iOMEDICO AG 50
Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12
Next Page